Cost-effectiveness of HPV 16, 18 vaccination in Brazil

Goldie, Sue J.; Kim, Jane J.; Kobus, Katie; Goldhaber-Fiebert, Jeremy D.; Salomon, Joshua A.; O'Shea, Meredith; Bosch, F. Xavier; Sanjosé, Sílvia de; Franco, Eduardo L.

doi:10.1016/j.vaccine.2007.05.058

Cited by 150 publications

(159 citation statements)

References 29 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…In response to these needs, we conducted a series of analyses focused on the assessment of HPV16,18 adolescent vaccination for girls in low-and middleincome countries. [16][17][18][19][20][21][22] This paper summarises the most salient features from analyses focusing on 72 GAVI-eligible countries and 33 Latin American and Caribbean countries.…”

Section: Challenging Decisions About Cervical Cancer Preventionmentioning

confidence: 99%

“…Documentation of model development, data sources, data analysis and synthesis methods, and analytic assumptions may be found in recent publications and their respective appendices. [16][17][18][19][20][21][22][29][30][31] Analyses assumed the vaccine would be given to girls prior to age 12 (before sexual debut), was effective in preventing HPV 16 and 18 infection if used in girls with no prior infection, and provided life-long immunity. We adhered to standard guidelines for economic evaluation.…”

Section: Analytic Overviewmentioning

confidence: 99%

“…staff, supplies, equipment, and specimen transport), programmatic costs, and women's time and transportation costs were included. 7,16,34 …”

Section: Analytic Overviewmentioning

confidence: 99%

“…become more attractive) by 80%. 17,18 Sensitivity analyses that explore the influence of model input parameters, assumptions, and key uncertainties have been previously published for Brazil, Viet Nam and India, 16,21,22 as well as several other countries. 7,8,12,14,[17][18][19]41 Comments Our general findings indicate that making an HPV16,18 vaccine accessible to 70% of young adolescent girls in the 72 poorest GAVI-eligible countries could prevent the future deaths of about three million women vaccinated in the next decade.…”

Section: Sj Goldie Et Al / Reproductive Health Matters 2008;16(32):86-96mentioning

confidence: 99%

“…Model-based predictions of longterm vaccine benefits are dependent on several uncertain assumptions. 12, 15,16,20,31,41,45 The long-term duration of vaccine-induced protection, necessity for a booster, and degree and duration of cross-strain protection against other oncogenic HPV types not included in the vaccine are not yet known. Other uncertainties are the efficacy of HPV vaccines in settings with high HIV prevalence, behaviour of non-targeted high-risk HPV types following vaccination, and magnitude of herd immunity.…”

Section: Sj Goldie Et Al / Reproductive Health Matters 2008;16(32):86-96mentioning

confidence: 99%

See 4 more Smart Citations

Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

Goldie¹,

O'Shea²,

Díaz

et al. 2008

Reproductive Health Matters

View full text Add to dashboard Cite

Section: Challenging Decisions About Cervical Cancer Preventionmentioning

confidence: 99%

Section: Analytic Overviewmentioning

confidence: 99%

“…staff, supplies, equipment, and specimen transport), programmatic costs, and women's time and transportation costs were included. 7,16,34 …”

Section: Analytic Overviewmentioning

confidence: 99%

Section: Sj Goldie Et Al / Reproductive Health Matters 2008;16(32):86-96mentioning

confidence: 99%

Section: Sj Goldie Et Al / Reproductive Health Matters 2008;16(32):86-96mentioning

confidence: 99%

See 3 more Smart Citations

Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

Goldie¹,

O'Shea²,

Díaz

et al. 2008

Reproductive Health Matters

View full text Add to dashboard Cite

Metrics for evaluating patient navigation during cancer diagnosis and treatment

Guadagnolo

Dohan

Raich

2011

Cancer

View full text Add to dashboard Cite

Background Racial and ethnic minorities as well as other vulnerable populations experience disparate cancer-related health outcomes. Patient navigation is an emerging health care delivery innovation that offers promise in improving quality of cancer care delivery to these patients who experience unique health access barriers. Metrics are needed to evaluate whether patient navigation can improve quality of care delivery, health outcomes, and overall value in health care during diagnosis and treatment of cancer. Methods Information regarding the current state of the science examining patient navigation interventions was gathered via search of the published scientific literature. A focus group of providers, patient navigators, and health policy experts was convened as part of the Patient Navigation Leadership Summit sponsored by the American Cancer Society. Key metrics were identified for assessing the efficacy of patient navigation in cancer diagnosis and treatment. Results Patient navigation data exists for all stages of cancer care; however, the literature is more robust for its implementation during prevention, screening, and early diagnostic work-up of cancer. Relatively fewer data are reported for outcomes and efficacy of patient navigation during cancer treatment. Metrics are proposed for a policy-relevant research agenda to evaluate the efficacy of patient navigation in cancer diagnosis and treatment. Conclusions Patient navigation is understudied with respect to its use in cancer diagnosis and treatment. Core metrics are defined to evaluate its efficacy in improving outcomes and mitigating health access barriers.

show abstract

Cervical cancer control in Latin America: A call to action

Bychkovsky

Ferreyra²,

Strasser‐Weippl

et al. 2015

Cancer

View full text Add to dashboard Cite

Cervical cancer (CC) is second most common cause of cancer in Latin America and is a leading cause of cancer mortality among women. In 2015, an estimated 74,488 women will be diagnosed with CC in Latin America and 31,303 will die of the disease. CC mortality is projected to increase by 45% by 2030 despite human papillomavirus (HPV) vaccination and screening efforts. In this setting, the goal was of the current study was to examine CC control efforts in Latin America and identify deficiencies in these efforts that could be addressed to reduce CC incidence and mortality. The authors found that HPV vaccination has been introduced in the majority of Latin American countries, and there is now a need to monitor the success (or shortcomings) of these programs and to ensure that these programs are sustainable. This topic was also reviewed in light of emerging data demonstrating that visual inspection with acetic acid and HPV DNA testing without Papanicolaou tests have efficacy from a screening perspective and are good alternatives to cytology-based screening programs. Overall, there is a need to build capacity for CC control in Latin America and the best strategy will depend on the country/region and must be tailored to meet the needs of the population as well as available resources. Cancer 2016;122:502-14.

show abstract

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

Cited by 150 publications

References 29 publications

Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

Metrics for evaluating patient navigation during cancer diagnosis and treatment

Cervical cancer control in Latin America: A call to action

Contact Info

Product

Resources

About